An observational study in Neuromuscular Disorders, Motor Development and Muscle Tone, sponsored by Shirley Ryan AbilityLab. Recruiting at 2 sites in United States. Open to participants aged 0 Months to 8 Weeks. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Shirley Ryan AbilityLab · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Neuromuscular Diseases with a site in United States — 29 open to participants now, 39 under way, 4 of them phase 3. Neuromuscular Diseases · United States.
Among the 120 studies in Neuromuscular Diseases with a site in United States, this one is the 32nd largest by planned enrollment of the 46 observational ones that give a count, is one of 10 that started in 2025, is one of 46 observational ones, reaches primary completion later than 8 of the 38 other live ones, and was the 105th registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →29 of the 120 studies in Neuromuscular Diseases with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18–70
David Toupin · Sites in United States
Ages 6–12
University of Pennsylvania · Sites in United States
Ages 18+
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Northwestern University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: 0 Months to 8 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 20
First in 1984; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 72 across 144 observational studies indexed under Neuromuscular Diseases.
Median enrollment 48 across the 72 interventional studies, 82 across the 46 observational. Of the 77 that completed or were terminated, 28 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 120 have an industry lead sponsor. The 10 most frequent:
Shirley Ryan AbilityLab is the lead sponsor of 181 studies on the registry; 44 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
Shirley Ryan AbilityLab has 2 studies filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuromuscular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03797183University of Colorado, DenverGenesis Electrical Impedance Tomography (EIT): A Preliminary Study | 2026-11 |
| NCT06970522Shirley Ryan AbilityLabWearable Sensors to Detect Atypical Muscle Activation in Young Infants | 2026-12-31 |
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07223632Vanda PharmaceuticalsTreatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 120 studies in Neuromuscular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if wearable sensor technology can be used to evaluate muscle activity and/or identify atypical muscle tone in infants up to 48 weeks postmenstrual age (8 weeks corrected age). These sensors are placed on the surface of the skin and record data about a child's body movements and muscle activity.
Infants presenting with atypical muscle tone based on clinical expertise along with infants expected to have typical development.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Correlation Between EMG Data and Observed Muscle Tone Before 8 Weeks Corrected Age
Correlation of EMG sensor data and Hammersmith Neonatal Neurological Exam (HNNE) short form score, assessed before 8 weeks corrected age.
Time frame: Before 8 weeks corrected age
Estimation of Clinical Scores Performed Before 8 Weeks Corrected Age Using EMG Data
Error between true clinical test scores and estimated scores using EMG sensor data, assessed before 8 weeks corrected age.
Time frame: Before 8 weeks corrected age
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.